Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKURA extension study of long-term safety of intravitreal DE-109 in posterior segment non-infectious uveitis
2014-004042-96Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sirolimus in non-infectious posterior uveitis (NIPU) and posterior uveitis, sponsored by Santen Pharmaceutical. Primary endpoint: Long-term safety of DE-109 440 micrograms. Started Mar 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
non-infectious posterior uveitis (NIPU)posterior uveitis
Beyond the preview
Go deeper on 2014-004042-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004042-96.